The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. - Wikidata - wikimedia - TriplyDB

The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.

The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.

http://www.wikidata.org/entity/Q33739428

about

Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998-2002.Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations.Familial breast cancer: Genetic counseling over time, including patients´ expectations and initiators considering the Angelina Jolie effect.Risk of asynchronous contralateral breast cancer: multiple approaches for a complex issue.High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer.Impact of Prophylactic Mastectomy in BRCA1/2 Mutation Carriers Breast cancer risks and risk prediction models.Tumor characteristics and prognosis in familial breast cancer.Estimating a population cumulative incidence under calendar time trends.Risk-reducing Surgery in Women at Risk for Familial Breast or Ovarian Cancer.Breast Cancer Survivors' Knowledge of Hereditary Breast and Ovarian Cancer following Genetic Counseling: An Exploration of General and Survivor-Specific Knowledge Items.Contralateral breast cancer risk in BRCA1/2-positive families needs to be adjusted for phenocopy rates particularly in second-degree untested relatives.Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status.Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial.Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors.Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer.Women at familial risk of breast cancer electing for prophylactic mastectomy: frequencies, procedures, and decision-making characteristics.Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.A model for individualized risk prediction of contralateral breast cancer.Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? results from a randomized clinical trial.Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer.Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.Prophylactic Surgery: For Whom, When and How?Preoperative Breast Magnetic Resonance Imaging Use by Breast Density and Family History of Breast Cancer.Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.[Risk-adapted surveillance: focus on familial breast and ovarian cancer].Oncology health professionals' attitudes toward treatment-focused genetic testing for women newly diagnosed with breast cancer.Risikofaktoren und Prävention des Mammakarzinoms Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Brea

P2860

Q30692732-F126FF7C-B9B7-4B64-AB72-645328887434 Q30896495-CF2C8B70-AF47-414B-887A-E614540825DA Q33691512-72B3A40C-87D7-4A33-9F5E-7A74D937F47A Q33727903-27E1EC4E-44B6-4A01-98C1-13EDC5592DB6 Q33972981-A5A0148C-1F0A-4FE6-AA4A-E0FDD39C30CE Q34240064-3DB64800-0522-4D4E-90B2-AE67AA00D841 Q35050959-FBA3971D-290F-4C2E-9B38-9558377A57D1 Q35399596-8E4B1D83-47A1-4641-808C-AE0379D95D0A Q36207051-0BDEAFD5-BA5D-4567-9EED-A955089580C2 Q36246600-7CB1579C-B4A8-47E8-AEDB-A2F2A54C393E Q36295137-89CAE928-8E35-45F8-ADAC-74EA34E21C69 Q36567487-01A05C1C-DA8D-44F3-8F76-04025394FE68 Q36903179-464B2FCE-59B1-49DC-AC9B-1943F1F6CD59 Q37583113-97C9EF21-D59C-48E8-9573-2F643063AD93 Q37594381-3A361808-F2E7-4D87-9F65-B8A35E38A50F Q38093037-6431AEE3-2FE2-4868-95EB-EF8117115ECA Q38763072-89C9DCAC-4E85-4531-992A-91981FEAA22B Q38821731-BA651956-F261-44FA-97F0-695AD1D49C75 Q38851169-754A2924-3F60-4E07-A4A1-41B9A5BAA6A7 Q39213394-58FC32C9-300E-447C-ACF9-6A7297EF13BF Q41024301-1A1787BB-E37C-4F62-802E-DC237365F48C Q41088085-B98C1EA1-3B74-48A1-8926-5C7465D17BC2 Q41517367-9B0A4E39-26EE-42B7-9F9C-18D1573FCE89 Q49885181-3222EA8F-A92A-41C7-A0CD-BEE2E20EE63F Q50045226-56D9A6BA-6A48-4495-A99F-13AD85D1385C Q50195463-18DA5B29-C077-4554-9F4E-E2FD30E87E3E Q51239985-98EE8C08-94F5-4129-B5F3-49DE8AE60CAB Q54257613-1B3348E3-A302-44A0-997D-048188C8220B Q56624494-1C20098D-C42D-4A26-BFC1-445880667CD0 Q58124814-7D4E5636-B84A-4596-9F32-F17CDD6BD555

P2860

The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.

http://www.wikidata.org/entity/Q33739428

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

The risk of contralateral brea ...... a retrospective cohort study.

@ast

The risk of contralateral brea ...... a retrospective cohort study.

@en

type

label

The risk of contralateral brea ...... a retrospective cohort study.

@ast

The risk of contralateral brea ...... a retrospective cohort study.

@en

prefLabel

The risk of contralateral brea ...... a retrospective cohort study.

@ast

The risk of contralateral brea ...... a retrospective cohort study.

@en

P1433

Q33739428-7CF3C088-9BE7-458F-BBA2-B32B2BB76FD9

P1476

Q33739428-0764B390-A0F7-43DF-B9E8-E54C42F4F231

P2093

Q33739428-0216CFE0-9DCD-48BB-A4E9-234D7115A2C4

Q33739428-3099D1AC-4C39-4490-9D85-6566A699A9A2

Q33739428-4931CF5C-EA6D-4DED-8EE5-9B2A21512BC5

Q33739428-49852D1C-F9FE-46ED-AD43-A57CEC14995B

Q33739428-5015FF67-A1A5-4157-B779-41B8DCD7638A

Q33739428-7D1021E4-9A98-4CBF-B9AD-903F56FD6AD0

Q33739428-8F96022B-9A65-4673-9A0B-0FE32BB886C3

Q33739428-9341FF21-3333-4775-A9CF-DD239822EEFF

Q33739428-A008876B-FA3E-43E4-BA61-DFBC47E807C4

Q33739428-AE561AA1-A0B3-4BD7-B7DB-67BA0EFC2651

P2860

Q33739428-03DD4EDB-A789-454A-AFCE-7256A5C70C82

Q33739428-0A7018F1-0FE4-4A4F-BA02-1DC6B60B9F6D

Q33739428-0BFDC908-7DAD-4FC2-8034-EB626048EBDA

Q33739428-1650DEBC-6A63-4B03-A57B-FF8EC7D9AA99

Q33739428-216F6116-1DB8-4E00-8C38-E1701AC910E0

Q33739428-2CACE573-A22C-46A4-ABFC-433F2642FA52

Q33739428-3F22A64C-2E0B-4141-9CA4-6D139D779484

Q33739428-402B26DD-D470-4454-9A90-AF1C4A345534

Q33739428-50E29C12-177B-449C-8BBB-F48D0B99D60F

Q33739428-54BC239F-C840-4E02-A491-E561991BA93C

P2888

Q33739428-B399A986-18E3-4E8D-BF79-9924C5FD385F

P304

Q33739428-59EDD3DC-03E9-4228-8B9B-0F7C2399832C

P31

Q33739428-EB573BCD-7978-4A26-A534-ADF72A049889

P356

Q33739428-13FBDF48-EC50-4AFD-9928-580971B2CDC1

P433

Q33739428-95A62D35-3D64-48F8-B977-8C3C620E0D40

P478

Q33739428-A52B731E-1232-40FC-A9DD-7A285C62F77F

P50

Q33739428-04F82752-9DAB-4104-B6C1-38596A632F0C

Q33739428-822CEE14-7B83-431F-B390-1AC665DE0B29

Q33739428-82D2E8F8-64D6-4EDD-AA54-E9E581BA5966

Q33739428-C896B98B-D2DE-45E2-AED4-92D521E3D911

P577

Q33739428-DBB7054D-8F9D-4E03-B98F-1EFE1379D934

P5875

Q33739428-A5043903-CA43-47A5-9515-0135DCC922CB

P6179

Q33739428-180640A1-6F56-4D2C-A5B5-EB149153FD56

P698

Q33739428-7D502499-C346-44A7-B75F-535B16CC8CA9

P932

Q33739428-DB7A190F-A20D-48C9-B2FA-7DD477F6BEAC

P356

P1433

Breast Cancer Research

P1476

The risk of contralateral brea ...... a retrospective cohort study.

@en

P2093

Christoph Mundhenke

http://www.w3.org/2001/XMLSchema#string

Dominic Varga

http://www.w3.org/2001/XMLSchema#string

Dorothea Gadzicki

http://www.w3.org/2001/XMLSchema#string

Karin Kast

http://www.w3.org/2001/XMLSchema#string

Kerstin Rhiem

http://www.w3.org/2001/XMLSchema#string

Marion Kiechle

http://www.w3.org/2001/XMLSchema#string

Michael Golatta

http://www.w3.org/2001/XMLSchema#string

Monika Graeser

http://www.w3.org/2001/XMLSchema#string

Nina Ditsch

http://www.w3.org/2001/XMLSchema#string

Silke Zachariae

http://www.w3.org/2001/XMLSchema#string

P2860

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium

Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.

Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.

Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Declining incidence of contralateral breast cancer in the United States from 1975 to 2006

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

P2888

P304

R156

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR3369

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Rita Schmutzler

Sabine Preisler-Adams

Christoph Engel

P577

2012-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233874967

http://www.w3.org/2001/XMLSchema#string

P6179

1034605521

http://www.w3.org/2001/XMLSchema#string

P698

23216834

http://www.w3.org/2001/XMLSchema#string

P932

4053142

http://www.w3.org/2001/XMLSchema#string